Joseph Catanzaro
Stock Analyst at Piper Sandler
(n/a)
# 2,947
Out of 5,008 analysts
97
Total ratings
n/a
Success rate
-65.46%
Average return
Main Sectors:
Stocks Rated by Joseph Catanzaro
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IBRX ImmunityBio | Upgrades: Overweight | $4.25 → $5 | $2.50 | +100.00% | 5 | May 20, 2025 | |
| CTMX CytomX Therapeutics | Maintains: Overweight | $2.5 → $5 | $3.33 | +50.15% | 5 | May 15, 2025 | |
| IOVA Iovance Biotherapeutics | Maintains: Neutral | $7.5 → $6 | $2.18 | +175.23% | 10 | Feb 28, 2025 | |
| SDGR Schrödinger | Maintains: Overweight | $50 → $45 | $20.16 | +123.21% | 3 | Feb 27, 2025 | |
| MRUS Merus | Initiates: Overweight | $84 | $94.39 | -11.01% | 1 | Feb 13, 2025 | |
| GILD Gilead Sciences | Maintains: Overweight | $105 → $110 | $116.78 | -5.81% | 5 | Feb 12, 2025 | |
| EXEL Exelixis | Maintains: Overweight | $37 → $38 | $39.63 | -4.11% | 4 | Feb 12, 2025 | |
| KROS Keros Therapeutics | Maintains: Overweight | $40 → $15 | $15.65 | -4.15% | 3 | Jan 17, 2025 | |
| HALO Halozyme Therapeutics | Maintains: Neutral | $52 → $53 | $66.02 | -19.72% | 9 | Jan 10, 2025 | |
| CRDF Cardiff Oncology | Maintains: Overweight | $7 → $10 | $2.24 | +346.43% | 4 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $57 → $70 | $46.57 | +50.31% | 2 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $15 → $2 | $0.21 | +875.61% | 2 | Nov 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $10 → $19 | $1.85 | +929.81% | 5 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $19 | $9.41 | +101.91% | 1 | Oct 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $12 → $15 | $3.91 | +283.63% | 3 | Sep 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $36 | $46.94 | -23.31% | 2 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $40 | $7.41 | +439.81% | 5 | Jul 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $15 | $11.52 | +30.21% | 4 | Jun 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $35 | $9.83 | +256.05% | 1 | Jun 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $4.5 | $1.13 | +298.23% | 1 | May 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $26 → $30 | $1.91 | +1,470.68% | 2 | Apr 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $20 | $1.23 | +1,526.02% | 1 | Apr 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $15 → $10 | $4.37 | +128.83% | 4 | Mar 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $18 | $7.29 | +146.91% | 1 | Feb 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $30 → $25 | $1.82 | +1,273.63% | 3 | Oct 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $15 → $1.75 | $5.04 | -65.28% | 2 | May 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $18 → $20 | $20.82 | -3.94% | 1 | Dec 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $25 → $1.5 | $1.78 | -15.73% | 1 | May 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $240 → $200 | $11.26 | +1,676.77% | 2 | Mar 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $35 | $7.01 | +399.29% | 1 | Jun 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $60 | $1.06 | +5,560.38% | 1 | Mar 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $28 → $18 | $2.64 | +581.82% | 3 | Apr 7, 2020 |
ImmunityBio
May 20, 2025
Upgrades: Overweight
Price Target: $4.25 → $5
Current: $2.50
Upside: +100.00%
CytomX Therapeutics
May 15, 2025
Maintains: Overweight
Price Target: $2.5 → $5
Current: $3.33
Upside: +50.15%
Iovance Biotherapeutics
Feb 28, 2025
Maintains: Neutral
Price Target: $7.5 → $6
Current: $2.18
Upside: +175.23%
Schrödinger
Feb 27, 2025
Maintains: Overweight
Price Target: $50 → $45
Current: $20.16
Upside: +123.21%
Merus
Feb 13, 2025
Initiates: Overweight
Price Target: $84
Current: $94.39
Upside: -11.01%
Gilead Sciences
Feb 12, 2025
Maintains: Overweight
Price Target: $105 → $110
Current: $116.78
Upside: -5.81%
Exelixis
Feb 12, 2025
Maintains: Overweight
Price Target: $37 → $38
Current: $39.63
Upside: -4.11%
Keros Therapeutics
Jan 17, 2025
Maintains: Overweight
Price Target: $40 → $15
Current: $15.65
Upside: -4.15%
Halozyme Therapeutics
Jan 10, 2025
Maintains: Neutral
Price Target: $52 → $53
Current: $66.02
Upside: -19.72%
Cardiff Oncology
Dec 13, 2024
Maintains: Overweight
Price Target: $7 → $10
Current: $2.24
Upside: +346.43%
Nov 7, 2024
Maintains: Overweight
Price Target: $57 → $70
Current: $46.57
Upside: +50.31%
Nov 4, 2024
Downgrades: Neutral
Price Target: $15 → $2
Current: $0.21
Upside: +875.61%
Oct 31, 2024
Maintains: Overweight
Price Target: $10 → $19
Current: $1.85
Upside: +929.81%
Oct 7, 2024
Initiates: Overweight
Price Target: $19
Current: $9.41
Upside: +101.91%
Sep 23, 2024
Maintains: Overweight
Price Target: $12 → $15
Current: $3.91
Upside: +283.63%
Aug 15, 2024
Maintains: Overweight
Price Target: $36
Current: $46.94
Upside: -23.31%
Jul 8, 2024
Maintains: Overweight
Price Target: $40
Current: $7.41
Upside: +439.81%
Jun 14, 2024
Maintains: Overweight
Price Target: $15
Current: $11.52
Upside: +30.21%
Jun 5, 2024
Maintains: Overweight
Price Target: $35
Current: $9.83
Upside: +256.05%
May 16, 2024
Initiates: Overweight
Price Target: $4.5
Current: $1.13
Upside: +298.23%
Apr 25, 2024
Maintains: Overweight
Price Target: $26 → $30
Current: $1.91
Upside: +1,470.68%
Apr 22, 2024
Initiates: Overweight
Price Target: $20
Current: $1.23
Upside: +1,526.02%
Mar 18, 2024
Maintains: Overweight
Price Target: $15 → $10
Current: $4.37
Upside: +128.83%
Feb 12, 2024
Initiates: Overweight
Price Target: $18
Current: $7.29
Upside: +146.91%
Oct 16, 2023
Maintains: Overweight
Price Target: $30 → $25
Current: $1.82
Upside: +1,273.63%
May 23, 2023
Downgrades: Neutral
Price Target: $15 → $1.75
Current: $5.04
Upside: -65.28%
Dec 20, 2022
Maintains: Overweight
Price Target: $18 → $20
Current: $20.82
Upside: -3.94%
May 5, 2022
Downgrades: Neutral
Price Target: $25 → $1.5
Current: $1.78
Upside: -15.73%
Mar 10, 2022
Maintains: Overweight
Price Target: $240 → $200
Current: $11.26
Upside: +1,676.77%
Jun 21, 2021
Initiates: Overweight
Price Target: $35
Current: $7.01
Upside: +399.29%
Mar 25, 2021
Initiates: Overweight
Price Target: $60
Current: $1.06
Upside: +5,560.38%
Apr 7, 2020
Maintains: Overweight
Price Target: $28 → $18
Current: $2.64
Upside: +581.82%